New drug 9MW1911 tested for safety in first human trial
NCT ID NCT05803902
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 trial tested the safety and tolerability of a new drug called 9MW1911 in 48 healthy adults. The drug is being developed for asthma, COPD, and atopic dermatitis. Participants received either the drug or a placebo by IV infusion, and researchers monitored side effects and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 9MW1911 injection
- What this could lead to
- If successful, this could lead to a new treatment option for asthma, COPD, or atopic dermatitis.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not patients. It only checks safety and dosing, not whether the drug works for the diseases. Many drugs fail in later stages.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Hospital
Beijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can a new injection calm severe eczema when creams fall short?
- Blood test may curb antibiotic overuse in COPD attacks
- Can a new biologic calm severe eczema?
- Can pressurized breathing boost mucus clearance in lung disease?
- HIV and hidden health risks: a major study probes the link